Hans Bundgaard, “Novel Chemical Approaches in Prodrug Design,” Drugs of the Future, 16(5):443-458 (1991). |
Yung-chi Cheng and William H. Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction,” Biochemical Pharmacology, 22:3099-3108 (1973). |
David Fleisher, Ramon Bong and Barbra H, Stewart, “Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs,” Advanced Drug Delivery Reviews, 19:115-130 (1996). |
Irwin H. Segel, Enzyme Kinetics, 1975, John Wiley & Sims, New York, pp. 100-125. |
James A. Ostrem, et al., “Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry,” Biochemistry, 37:1053-1059 (1998). |
Oyo Mitsunobu, “The Use of Diethyl Azodicarboxylate and Triphenylphoshine in Synthesis and Transformation of Natural Products,”0 Synthesis, pp. 1-28 (1981). |